deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT05172193

Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)

A Phase II Non-Randomized Open Labelled Clinical Trial to Evaluate the Safety & Immunogenicity of SARS-COV-2 Vaccine (Vero Cell) Inactivated as A Booster Dose

Sponsor: PT. Kimia Farma (Persero) Tbk

Conditions COVID-19
Updated 5 times since 2022 Last updated: Sep 4, 2022 Started: Dec 31, 2021 Primary completion: Sep 30, 2023 Completion: Sep 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on COVID-19, this trial is ongoing. The trial is conducted by PT. Kimia Farma (Persero) Tbk and has accumulated 5 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshotNot Yet Recruiting~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshotRecruiting~Oct 2024 – present · 21 months · monthly snapshotUnknown

Change History

5 versions recorded
  1. Oct 2024 — Present [monthly]

    Unknown PHASE2

    Status: RecruitingUnknown

  2. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  5. Jan 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • PT. Kimia Farma (Persero) Tbk
Data source: PT. Kimia Farma (Persero) Tbk

For direct contact, visit the study record on ClinicalTrials.gov .